Sporadik Medüller Tiroid Kanserli Bir Hastada Nadir Görülen RET Proto-Onkogen Mutasyonu: D631Y
Amaç: Multipl endokrin neoplazi tip 2 (MEN2), otozomal dominant kalıtım sergileyen bir sendromolup, germ hattında meydana gelen yanlış anlamlı RET proto-onkogen mutasyonları ile ilişkilendirilmiştir.Mutasyon taşıyıcılarının yaklaşık %90’ının medüller tiroid karsinomu (MTK) geliştirdiği bilinmektedir.Hastalarda RET mutasyon taraması ile genetik tanı sağlanmakta ve ailede henüz semptomgöstermeyen bireylerin mutasyon tipine göre önleyici cerrahi müdahaleye yönlendirilmeleri sağlanabilmektedir.Bu bağlamda, çalışmamız sporadik MTK teşhisli bireyin klinik takiplerinin sağlanması veiki oğlu ile birlikte RET proto-onkogen genetik tanılarının gerçekleştirilmesini amaçlamıştır.Yöntem: İndeks vakanın detaylı klinik değerlendirmeleri ile pre-operatuvar ve post-operatif histopatolojikincelemeleri gerçekleştirilmiştir. Boyun ultrasonografisi ve biyokimyasal değerlendirmeler dedahil olmak üzere rutin klinik takip yapılmıştır.RET proto-onkogenin rutin genetik tanısı, genin 10, 11, 13-16’ıncı ekzonlarının PZR amplifikasyonunutakiben Sanger dizilemesi yöntemleri ile gerçekleştirilmiştir. Mutasyon taşıyan ekzon hastanınasemptomatik iki oğlunda taranmıştır.Bulgular: İndeks vaka klinik incelemeler ve histopatolojik tanı ile sporadik MTK tanısı almıştır. RETgen mutasyon taraması sonucunda hastanın 11. ekzonunda c.1891G>T (D631Y) mutasyonu ile 11 ve13. ekzonlarında sırasıyla rs1799939 ve rs1800861 polimorfizmleri tespit edilmiştir. Hastanın her ikioğlu da RET geni 11. ekzon için taranmış ancak mutasyon taşımadıkları bildirilmiştir.Sonuç: Genetik tanı hem indeks vakanın sporadik MTK tanısını kesinleştirmiş hem de oğullarındasağlıklı olduğunu göstermiştir. Bu çalışma, literatürde ilk defa feokromasitomaya eşlik etmeyen sporadikmedüller tiroid kanserli bir olguda D631Y mutasyon varlığını göstermektedir.
A RARE RET PROTO-ONCOGENE MUTATION IN A SPORADIC MEDULLARY THYROID CARCINOMA: D631Y
Objectives: Multiple endocrine neoplasia type 2 (MEN2) syndrome is associated with germ-linemissense mutations in RET proto-oncogene, inherited in an autosomal dominant manner. Approximately90% of RET mutations were shown to develop medullary thyroid carcinoma (MTK). Genetictesting is accomplished through RET mutation screen and asymptomatic first degree relatives of indexcases are recommended to be tested for preventative surgical operations. Thus, we aimed to performclinical follow-up of a sporadic MTK case, as well as to carry out RET proto-oncogen genetic diagnosison the index case and her two sons.Materials and Methods: Index case has been subjected to detailed clinical evaluations, as well asto pre- and post-operative hystopathological examinations. Routine clinical follow-up including neckultrasonography and biochemical evaluations have been performed. RET proto-oncogene routinediag-nostic test was performed on 10, 11, 13-16th exons of the gene through PCR-amplificationfollowed by Sanger sequencing. Exon with a mutation was screened on index cases’ two sons.Results: Clinical evaluations diagnosed index case as MTK. RET genetic screen revealed c.1891G>T(D631Y) in 11th exon confirming diagnosis. The two sons were found negative for RET gene mutationsin their 11th exons.Conclusion: Genetic diagnosis both confirmed clinical diagnosis of the index case and showed thatthe sons are healthy. This is the first report of a D631Y mutation in a case of sporadic medullary thyroidcancer without pheochromocytoma in the literature.
___
- 1. Eng C, Clayton D, Schuffenecker I, Lenoir G,
Cote G, Gagel RF, van Amstel HKP, Lips CJ,
Nishisho I, Takai SI, Marsh DJ, Robinson BG,
Frank-Raue K, Raue F, Xue F, Noll WW, Romei
C, Pacini F, Fink M, Niederle B, Zeden- ius
J, Nordenskjold M, Komminoth P, Hendy GN,
Gharib H, Thibodeau SN, Lacroix A, Frilling A,
Ponder BAJ, Mulligan LM. The relationship
between specific RET proto-oncogene mutations
and disease pheno-type in multiple
endocrine neoplasia type 2. International
RET mutation consortium analysis JAMA.
1996; 276:1575-1579.
2. Pasquali D, Di Matteo FM, Renzullo A, Accardo
G, Esposito D, Barbato F, Colantuoni V,
Circelli L, Conzo G. Multiple endocrine neoplasia,
the old and the new: a mini review. G.
Chir 2012; 33(11–12): 370-373.
3. Donis-Keller H, Dou S, Chi D, Carlson KM,
Toshima K, Lairmore TC, Howe JR, Moley JF,
Goodfellow P, Wells SA. Mutations in the
RET proto-oncogene are associated with
MEN 2A and FMTK. Hum Mol Genet 1993; 2:
851–856.
4. Mulligan LM, Kwok JBJ, Healey CS, Elsdon
MJ, Eng C, Gardner E, Love DR, Mole SE,
Moore JK, Papi L, Ponder MA, Telenius H,
Tunnacliffe A, Ponder BAJ. Germ-line mutations
of the RET proto-oncogene in multiple
endocrine neoplasia type 2A. Nature.
1993; 363: 458–460.
5. Brandi ML, Gagel RF, Angeli A, Bilezikian
JP, Beck-Peccoz P, Bordi C, Conte-Devolx
B, Falchetti A, Gheri RG, Libroia A, Lips CJ,
Lombardi G, Mannelli M, Pacini F, Ponder BA,
Raue F, Skogseid B, Tamburrano G, Thakker
RV, Thompson NW, Tomassetti P, Tonelli F,
Wells SA Jr, Marx SJ. Guidelines for diagnosis
and therapy of MEN type 1 and type 2. J
Clin Endocrinol Metab 2001; 86: 5658–5671.
6. Machens A, Dralle H. Familial prevalence and
age of RET germline mutations: implications
for screening. Clin Endocrinol (Oxf). 2008;
69:81-87.
7. Machens A, Holzhausen HJ, Thanh PN, Dralle
H. Malignant progression from C-cell hyperplasia
to medullary thyroid carcinoma in
167 carriers of RET germline mutations.
Surgery 2003; 134:425-431.
8. Eng C. The RET proto-oncogene in multiple
endocrine neoplasia type 2 and Hirschsprung’s
disease. N Engl J Med 1996; 335:
943-951.
9. Kloos RT, Eng C, Evans DB, Francis GL, Gagel
RF, Gharib H, Moley JF, Pacini F, Ringel MD,
Schlumberger M, Wells SA Jr. Medullary
thyroid cancer: management guidelines of
the American Thyroid Association. Thyroid
2009; 19: 565-612.
10. Elston MS, Meyer-Rochow GY, Holdaway I,
Conaglen JV. Patients with RET D631Y Mutations
Most Commonly Present with Pheochromocytoma
and not Medullary Thyroid
Carcinoma. Horm Metab Res 2012; 44:
339-342.
11. Accardo G, Conzo G, Esposito D, Gambardella
C, Mazzella M, Castaldo F, Di Donna C, Polistena
A, Avenia N, Colantuoni V, Giugliano
D, Pasquali D. Genetics of medullary thyroid
cancer: An overview. Int J Surg 2017; 41: S2-
S6.
12. Fagin JA, Wells Jr. SA. Biologic and clinical
perspectives on thyroid cancer. N Engl J Med
2016; 15(375): 1054-1067.
13. Lindsey SC, Kunii IS, Germano-Neto F, Sittoni
MY, Camacho CP, Valente FO, Yang JH, Signorini
PS, Delcelo R, Cerutti JM, Maciel RM,
Dias-da-Silva MR. Extended RET gene
analysis in patients with apparently sporadic
medullary thyroid cancer: clinical benefits
and cost. Horm Cancer 2012; 3(4):181-186.
14. Santos MA, Quedas EP, Toledo Rde A, Lourenço
DM Jr, Toledo SP. Screening of RET
gene mutations in multiple endocrine
neoplasia type-2 using conformation sensitive
gel electrophoresis (CSGE). Arq Bras Endocrinol
Metabol 2007; 51(9): 1468-1476.
15. Zupan A, Glavač D. “he development of rapid
and accurate screening test for RET hotspot
somatic and germline mutations in MEN2 syndromes.
Exp Mol Pathol 2015; 99: 416-425.
16. Castinetti F, Moley J, Mulligan LM, Waguespack
SG. A Comprehensive Review On
MEN2B. Endocr Relat Cancer 2017; ERC-17-
0209.
17. Moline J ve Eng C. Multiple endocrine neoplasia
type 2: An overview. Genet Med 2011;
13: 755-764.
18. Fugazzola L, Muzza M, Mian C, Cordella
D, Barollo S, Alberti L, Cirello V, Dazzi D, Girelli
ME, Opocher G, Beck-Peccoz P, Persani
L. RET genotypes in sporadic medullary thyroid
cancer: studies in a large Italian series.
Clin Endocrinol Oxf 2008; 69:418-425.
19. Bae SJ, Kim D-J, Kim JY, Park SY, Choi SH,
Song YD, Ki C-S, Jae Hoon Chung JH. A Rare
Extracellular D631Y Germline Mutation of the
RET Proto-Oncogene in Two Korean Families
with Multiple Endocrine Neoplasia 2A. Thyroid
2006; 16(6): 609-614.